Shift

Transformative Power of Technology: Digital Transformation Summit 2024 Set to Redefine South Africa's Tech Landscape

Retrieved on: 
Friday, March 8, 2024

The much-anticipated Digital Transformation Summit is set to take place on March 15, 2024, at the prestigious Sandton Convention Centre.

Key Points: 
  • The much-anticipated Digital Transformation Summit is set to take place on March 15, 2024, at the prestigious Sandton Convention Centre.
  • The 27th Edition of the Digital Transformation Summit, South Africa, aims to delve deep into how organizations are embracing digital transformation, navigating challenges across various technologies, and bolstering cybersecurity measures.
  • Dr. Thabiso Njongwe, Chief Digital Transformation Officer, Absa Group, will discuss "Sustainable Digital Shift in South Africa: Challenges, Opportunities, and Inclusivity."
  • Join us at the Digital Transformation Summit South Africa on March 15th at the Sandton Convention Centre to be part of this transformative event.

Yamaha Expands bLU cRU Support for 2024 ATV and SxS Racing Season

Retrieved on: 
Thursday, March 7, 2024

MARIETTA, Ga., March 07, 2024 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA , is thrilled to announce significant expansions to its bLU cRU program for the 2024 Side-by-Side (SxS) and ATV racing seasons.

Key Points: 
  • MARIETTA, Ga., March 07, 2024 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA , is thrilled to announce significant expansions to its bLU cRU program for the 2024 Side-by-Side (SxS) and ATV racing seasons.
  • Donnie Luce, Yamaha's off-road racing coordinator, expresses, “We are incredibly excited to bolster our support for the 2024 ATV and SxS racing season.
  • Similarly, in the GNCC XC1 Pro ATV series, Brycen Neal of Phoenix Racing and Walker Fowler will compete for the XC1 Pro ATV title and $15,000 bLU cRU racing bonus on Yamaha YFZ450Rs.
  • New for 2024, Yamaha added bLU cRU support to the WORCS ATV classes.

Object Management Group Announces Leading Analyst Speakers for Transform! @ InfoComm 2024

Retrieved on: 
Wednesday, March 6, 2024

BOSTON, MA, March 06, 2024 (GLOBE NEWSWIRE) -- Object Management Group ®️ (OMG®️) announced that leading analysts will speak about the digital transformation market, about topics such as compliance, regulations, security, data analytics, and more  at Transform!

Key Points: 
  • BOSTON, MA, March 06, 2024 (GLOBE NEWSWIRE) -- Object Management Group ®️ (OMG®️) announced that leading analysts will speak about the digital transformation market, about topics such as compliance, regulations, security, data analytics, and more  at Transform!
  • “We’re excited to have renowned analysts discussing digital transformation and proposing strategies and best practices to assess and manage transformation effectively and efficiently.”
    Jim Morrish.
  • Jim is a respected Digital Transformation and Internet of Things industry expert with over 20 years of experience in strategy consulting, operations management, and telecoms research.
  • @InfoComm 2024, exhibitors will deliver hands-on experiences through an Innovation Hub and solutions showcases, highlighting new technology trends, breakthroughs, products, and services.

Cannabis Science Conference Spring 2024 announces new workshop powered by Cannabis Nurses Network™

Retrieved on: 
Friday, March 1, 2024

CRANBURY, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Cannabis Science Conference (CSC), the premier cannabis science conference focusing on analytical science, medical cannabis, cultivation and compliance, is thrilled to announce its new and exciting full-day workshop for CSC Spring 2024.

Key Points: 
  • CRANBURY, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Cannabis Science Conference (CSC), the premier cannabis science conference focusing on analytical science, medical cannabis, cultivation and compliance, is thrilled to announce its new and exciting full-day workshop for CSC Spring 2024.
  • Powered by Cannabis Nurses Network™ (CNN), the Cannabis Nursing: A Paradigm Shift in Healthcare workshop is scheduled for May 7, 2024 in Kansas City, Missouri, at the Kansas City Marriott Downtown.
  • The CSC Spring 2024 conference will be held from May 7 – May 9.
  • As the health care landscape evolves, nurses play a pivotal role in embracing innovative approaches to enhance patient well-being.

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

Retrieved on: 
Tuesday, February 27, 2024

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.
  • Overview: The NETSseq platform produces deep transcriptomic and epigenomic profiles from post-mortem human brain tissue.
  • One of these genes, KCNK10, is specifically expressed in astrocytes and oligodendrocytes, and its role in regulating glutamate uptake has been validated.
  • Therapeutic Targets, Mechanisms for Treatment: Astroglia; Poster Shift 2: Friday, March 8 - Saturday, March 9, 2024

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 20, 2024

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

SolarWinds Sponsors SQLBits 2024, Europe’s Largest Data Platform Conference

Retrieved on: 
Tuesday, March 5, 2024

SQLBits is Europe’s largest data platform conference, featuring 200 world-class speakers, more than 300 hours of content, and engaging networking opportunities.

Key Points: 
  • SQLBits is Europe’s largest data platform conference, featuring 200 world-class speakers, more than 300 hours of content, and engaging networking opportunities.
  • Attendees can deepen their knowledge of everything from the SQL Server® product suite and transactional data systems to the latest trends in big data, analytics, artificial intelligence (AI), and machine learning.
  • “SolarWinds database performance monitoring and observability solutions provide deep visibility and performance insight by simplifying the management of your most complex databases.
  • The SolarWinds database portfolio includes SolarWinds® Database Performance Analyzer for performance monitoring and analysis, SolarWinds SQL Sentry® for root cause analysis, and SolarWinds Database Observability , a SaaS solution built for DevOps and designed to help ensure optimal performance by monitoring open-source, cloud-enabled, and NoSQL databases.

Global Cold Chain Market for Pharmaceuticals Research Report 2024: Market Trends (2019-2022) and Forecasted Estimates (2023-2035) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024

This market report features an extensive study of the current market landscape, market size and future opportunities associated with the temperature controlled packaging in pharma cold chain market, during the forecast period.

Key Points: 
  • This market report features an extensive study of the current market landscape, market size and future opportunities associated with the temperature controlled packaging in pharma cold chain market, during the forecast period.
  • One of the primary objectives addressed in this market report was the estimation of the current market size and the future growth potential within the cold chain market for pharmaceuticals in the upcoming years.
  • Through a thorough consideration of various parameters, anticipated adoption trends, and validated by primary research, the report provides informed estimates on the expected evolution of the cold chain market for pharmaceuticals during the forecast period from 2023 to 2035.
  • Recent advancements in the cold chain monitoring market have revolutionized the cold chain industry.

Global Respiratory Infection Diagnostic Market Research Report 2024-2028 with Executive and Consultant Guides - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels

Key Points: 

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels
5.39 Tempus Announces COVID-19 Testing, Data Initiative
5.42 Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
5.43 Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Retrieved on: 
Tuesday, February 27, 2024

“The new treatment landscape for Alzheimer’s disease is beginning to take shape, and Alzheon’s simplified approach has an opportunity to transform the standard of care and improve access to treatment for Alzheimer’s patients.

Key Points: 
  • “The new treatment landscape for Alzheimer’s disease is beginning to take shape, and Alzheon’s simplified approach has an opportunity to transform the standard of care and improve access to treatment for Alzheimer’s patients.
  • ALZ-801’s efficacy data and favorable safety profile, showing no increased risk of vasogenic edema, underscore the differentiated clinical profile of our treatment,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • Results from our pivotal APOLLOE4 Phase 3 trial will set the stage for the potential NDA filing this year and commercial launch in 2025.”
    Alzheon presentations include two posters and two symposium presentations.
  • If the results of our study are positive, we will be moving quickly to bring an oral option to Alzheimer’s patients and their families,” said John Hey, PhD, Chief Scientific Officer.